## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Stock Traders Buy High Volume of Ionis Pharmaceuticals Call Options (NASDAQ:IONS)**
- Source: MarketBeat | 20260103T050911 | Somewhat-Bullish | Relevance: 100%
- Ionis Pharmaceuticals (NASDAQ:IONS) experienced a significant surge in options trading, with traders purchasing 4,064 call options, representing a 308% increase over average daily volume. Analyst sentiment remains largely positive, holding a "Moderate Buy" consensus rating with an average price target of $86.19. Despite this, company insiders have recently sold a substantial volume of shares, while institutional investors maintain a strong ownership stake of over 93%.

**2. Diversified Trust Co Invests $1.02 Million in Ionis Pharmaceuticals, Inc. $IONS**
- Source: MarketBeat | 20260103T040919 | Somewhat-Bullish | Relevance: 100%
- Diversified Trust Co recently purchased a new position of 15,633 shares in Ionis Pharmaceuticals (NASDAQ:IONS), valued at approximately $1.02 million during the third quarter. Institutional investors now collectively hold 93.86% of the company's stock, though company insiders sold a significant number of shares totaling almost $20 million in the last quarter. Wall Street analysts generally maintain a "Moderate Buy" rating for Ionis, with an average target price of $86.19.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Wells Fargo | $100 | $82 | +22% |
| 2025-12-17 | RBC Capital | $95 | $82 | +16% |
| 2025-12-15 | Leerink Partner | $100 | $85 | +18% |
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Wells Fargo | main | Overweight |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-15 | Leerink Partner | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($4.83M) |
| Sells | 11 ($3.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Insider selling cluster: $3.1M in recent transactions.
2. Valuation stretched: PEG 25.7x requires aggressive growth execution.
3. Elevated short interest (13.1%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 4 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (4 raises, avg +17%, $100 target (+28%)). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $12.7B |
| Beta | 0.28 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 13.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from -0.2% to -1.5% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.51x) but short-term weakness (below SMA20). RSI neutral at 49. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.47% (CS: 20) | Neutral |
| RSI_14 | 49.0 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 1.512x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $78.53
- **Stop Loss:** $74.21 (5.5% risk)
- **Target:** $82.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 199
- **Position Value:** $15,627.47
- **Portfolio %:** 15.63%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*